Incannex Healthcare Inc.
IXHLNasdaq
$3.17
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↓ -72.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$39.1M
Enterprise Value
-$35.3M
P/E
0.6
P/S
455.2
P/B
0.5
EV/EBITDA
—
PEG
—
FCF Yield
-32.0%
Dividend Yield
—
Revenue (TTM)
$86,000.00
Net Income (TTM)
-$48.4M
Free Cash Flow (TTM)
-$12.5M
Gross Margin
—
Operating Margin
-29494.2%
Net Margin
—
ROE
—
ROIC
-2555.9%
Debt / Equity
—
Net Cash
$74.5M
Return 1Y
-71.5%
Company profile
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.
- CEO
- Joel Bradley Latham
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Website
- www.incannex.com
Management & directors
- Latham JoelCEO and President
- Swan JosephCFO, Treasurer and Secretary
Roles derived from SEC Form 4 filings.
Earnings
IXHL Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.35↓ -94.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $12,000.00 | $86,000.00 |
| Gross profit | — | — | — | — | — | — | — |
| Operating income | — | — | — | -$49.7M | — | -$30.0M | -$23.8M |
| Net income | — | — | — | -$48.8M | — | -$18.5M | -$46.9M |
| Diluted EPS | — | — | — | -$3.32 | — | -$1.15 | -$1.35 |
| Operating cash flow | — | — | — | -$10.7M | — | -$15.8M | -$12.5M |
| Free cash flow | — | — | — | -$11.1M | — | -$16.1M | -$12.5M |
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -250341.7% | -27661.6% |
| Net margin | — | — | — | — | — | -153825.0% | -54517.4% |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $74,000.00 | $12,000.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.8M | -$6.3M | -$5.0M | -$5.0M | -$7.5M | -$6.8M | -$7.0M | -$4.0M |
| Net income | -$6.5M | -$5.4M | -$5.9M | -$4.0M | -$31.6M | -$6.4M | -$6.5M | -$3.9M |
| Diluted EPS | -$0.36 | -$0.29 | -$0.33 | -$6.19 | $5.46 | -$0.02 | -$0.02 | -$0.35 |
| Operating cash flow | -$3.6M | -$2.2M | -$5.6M | -$3.2M | -$1.5M | -$9.2M | -$4.6M | -$2.5M |
| Free cash flow | -$3.6M | — | — | -$3.2M | — | -$9.2M | -$4.6M | -$2.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | -8451.4% | -41700.0% | — | — | — | — | — |
| Net margin | — | -7324.3% | -49116.7% | — | — | — | — | — |
Company news
Jul 15, 2026
Jun 25, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-11-14 | Valentine Troy | Award | 11,302,608 | $0.00 | $0.00 | filing |
| 2025-11-14 | Clark Robert | Award | 1,686,956 | $0.00 | $0.00 | filing |
| 2025-11-14 | Widdows Peter | Award | 1,686,956 | $0.00 | $0.00 | filing |
| 2025-11-14 | Swan Joseph· CFO, Treasurer and Secretary | Award | 869,565 | $0.00 | $0.00 | filing |
| 2025-11-14 | Latham Joel· CEO and President | Award | 22,608,692 | $0.00 | $0.00 | filing |
| 2025-11-14 | Anastassov George | Award | 1,686,956 | $0.00 | $0.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.